The utility has been demonstrated in patients with hyperapoB (Cianflone et. al J. Clin. Invest. 1990, 85(3):722; Journal of Lipid Research, 39, 884-891, 1998) who demonstrated significantly reduced levels of ASP commensurate with increased hepatic VLDL production. .
[Detail]
Low chance ofside-effectsApplicable tovarious megakaryopoetic disorders
[Detail]